{"disease":{"id":"myelodysplastic-myeloproliferative-neoplasms","name":"myelodysplastic myeloproliferative neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02158858","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT07150468","title":"Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06270771","title":"OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Sunnybrook Health Sciences Centre","has_results":false},{"nct_id":"NCT03912064","title":"A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT07071155","title":"Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT04866056","title":"Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}